<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3620253</article-id><article-id pub-id-type="publisher-id">1129-2377-14-S1-P197</article-id><article-id pub-id-type="doi">10.1186/1129-2377-14-S1-P197</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Dodick</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Diener</surname><given-names>HC</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Turkel</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>DeGryse</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Brin</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib></contrib-group><aff id="I1"><label>1</label>Mayo Clinic Arizona, USA</aff><aff id="I2"><label>2</label>University of Essen, UK</aff><aff id="I3"><label>3</label>Allergan, USA</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>2</month><year>2013</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstract Book of The European Headache and Migraine Trust International Congress</named-content><named-content content-type="supplement-editor">Peter J Goadsby and Dominique Valade</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by EHMTIC Limited.</named-content></supplement><fpage>P197</fpage><lpage>P197</lpage><permissions><copyright-statement>Copyright &#x000a9;2013 Dodick et al; licensee Springer.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Dodick et al; licensee Springer.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.thejournalofheadacheandpain.com/content/14/S1/P197"/><conference><conf-date>20-23 September 2012</conf-date><conf-name>The European Headache and Migraine Trust International Congress</conf-name><conf-loc>London, UK</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Chronic migraine (CM) is a prevalent and disabling neurological disorder. OnabotulinumtoxinA is the only approved therapy specifically for CM. The results from randomized controlled trials often reflect, but rarely define, the spectrum of patient outcomes. The proportion of patients highly responsive to a therapy is an important endpoint and guide for clinicians and patients.</p></sec><sec><title>Objective</title><p>To determine the proportion of patients who are highly responsive (75% responder rate) to therapy in 2 double-blind, placebo-controlled, parallel studies (PREEMPT 1 &#x00026; 2).</p></sec><sec sec-type="methods"><title>Methods</title><p>PREEMPT (two phase 3 studies: 24-week, double-blind, placebo-controlled, parallel-group phase, followed by 32-week, open-label phase) evaluated onabotulinumtoxinA for prophylaxis of headaches in CM (15 days/month with headache lasting 4 hours/day or longer). Patients were randomized (1:1) to onabotulinumtoxinA (155-195U) or placebo every 12 weeks. The proportions of patients with 75% decrease from baseline in frequency of headache days, headache episodes, migraine days, migraine episodes, moderate/severe headache days, and total cumulative hours of headache on headache days were analyzed.</p></sec><sec sec-type="results"><title>Results</title><p>Pooled analyses (onabotulinumtoxinA n=688, placebo n=696) demonstrated a statistically significant between-group difference favoring onabotulinumtoxinA in the proportion of patients who had a 75% reduction from baseline in headache days at Week 24 (22.8% onabotulinumtoxinA, 15.5% placebo; p=0.002). For all above headache symptom measures, a significantly greater proportion of onabotulinumtoxinA-treated than placebo-treated patients had 75% decreases from baseline.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>PREEMPT supports the efficacy and tolerability of onabotulinumtoxinA for the prophylaxis of headache in adults with CM.[<xref ref-type="bibr" rid="B1">1</xref>] These data demonstrate that onabotulinumtoxinA treatment results in a significant 75% reduction in multiple headache symptom measures and highly substantial efficacy for a subpopulation of patients studied.</p></sec><sec><title>Support</title><p>Allergan, Inc.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Dodick</surname><given-names>DW</given-names></name><source>Headache</source><year>2010</year><volume>14</volume><issue>6</issue><fpage>921</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2010.01678.x</pub-id><pub-id pub-id-type="pmid">20487038</pub-id></mixed-citation></ref></ref-list></back></article>